Form 4: Revelation Biosciences CEO Acquires Shares in Recent Transaction
SEC Form 4 Filing
James Rolke, CEO of Revelation Biosciences, reports acquisition of company stock via a restricted stock grant.
Summary
- James Rolke, the CEO of Revelation Biosciences, acquired 30,095 shares of common stock on February 11, 2025, at a price of $3.87 per share.
- This transaction increased his direct holdings to 30,137 shares.
- The acquisition was a result of a restricted stock grant under the 2021 Equity Incentive Plan, which vests 100% on the grant date.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing. The CEO's stock purchase could be interpreted as a positive signal, but it's not explicitly stated as such.
Positives
- The CEO's acquisition of shares may signal confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into insider transactions, allowing investors to monitor the actions of company executives and directors.
Stakeholder Impact
- The CEO's stock purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/11/2025 | Date of the stock transaction. |
| 02/13/2025 | Date of signature on the Form 4 filing. |
Keywords
Revelation Biosciences, REVB, James Rolke, CEO, stock acquisition, Form 4, restricted stock grant, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.